Search Results for: First+in+Human

OncoArendi and Galapagos enter into exclusive collaboration on chitinase inhibitors in fibrosis

Mechelen, Belgium and Warsaw, Poland, 5 November 2020, 22:15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and OncoArendi Therapeutics SA (WSE: OAT), announced that they have signed an exclusive collaboration and license agreement for the

Read more

American Journal of Medicinal Chemistry distinguishes OncoArendi publication on OATD-01

A new publication about the discovery and preclinical characterization of OATD-01, authored by the scientists from OncoArendi Therapeutics, has just been accepted by the Journal of Medicinal Chemistry (J. Med. Chem). OATD-01 is a first-in-class chitinase

Read more

OncoArendi Therapeutics has received the final report from the phase Ib clinical trial of innovative drug candidate OATD-01

the report confirms the OATD-01 safety profile which justifies further clinical development of this experimental drugIn Q1 of 2021 the company plans to file for an approval of the next phase clinical trial in sarcoidosis patients

Read more

OncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients

OncoArendi Therapeutics - a clinical stage biotechnology company specializing in the discovery and development of innovative small molecule drugs continues the clinical development of its first-in-class experimental drug candidate for treatment of sarcoidosis and idiopathic pulmonary

Read more

Clinical trials of the OATD-01 molecule will enter the next phase

OncoArendi Therapeutics S.A., an innovative biotechnology company specializing in the quest, development and commercialization of new drugs used in the treatment of inflammatory and cancer diseases, on January 9 2019 received from the German National Institute

Read more

OncoArendi Therapeutics Gets Listed

OncoArendi Therapeutics S.A., an innovative, clinical stage, biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics for cancer and respiratory diseases, has filed documents with the Financial Supervision Authority, initiating the process aiming for the

Read more

OncoArendi Therapeutics to Begin the Phase 1 Clinical Evaluation of its Novel Class of Medicines

Healthy volunteers study initiated for OATD-01, an innovative therapy for the treatment of asthma Warsaw, Poland, October 9, 2017 - OncoArendi Therapeutics announced today that this week the Company will initiate a Phase 1 study designed

Read more

OncoArendi Therapeutics announced today that it has filed a Clinical Trial Application (CTA)

OATD-01 is a non-steroidal small molecule inhibitor, which has shown excellent pharmacokinetic properties in three species after oral dosing, and the overall DMPK profile that is consistent with the targeted once-a-day oral dosing in humans. OATD-01

Read more

OncoArendi Therapeutics Announces Selection of Its Second Clinical Development Candidate: OATD-02 For the Treatment of Multiple Cancers

Warsaw, Poland, June 21, 2017 / B3C newswire / -- During the first Company Presentation at the global BIO Conference in San Diego OncoArendi Therapeutics SA announced that it has selected OATD‑02 as its clinical development candidate

Read more